182 related articles for article (PubMed ID: 30241264)
1. Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.
Milligan MG; Bigger E; Abramson JS; Sohani AR; Zola M; Kayembe MKA; Medhin H; Suneja G; Lockman S; Chabner BA; Dryden-Peterson SL
J Glob Oncol; 2018 Sep; 4():1-11. PubMed ID: 30241264
[TBL] [Abstract][Full Text] [Related]
2. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
Barta SK; Xue X; Wang D; Tamari R; Lee JY; Mounier N; Kaplan LD; Ribera JM; Spina M; Tirelli U; Weiss R; Galicier L; Boue F; Wilson WH; Wyen C; Oriol A; Navarro JT; Dunleavy K; Little RF; Ratner L; Garcia O; Morgades M; Remick SC; Noy A; Sparano JA
Blood; 2013 Nov; 122(19):3251-62. PubMed ID: 24014242
[TBL] [Abstract][Full Text] [Related]
3. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
[TBL] [Abstract][Full Text] [Related]
4. CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi.
Gopal S; Fedoriw Y; Kaimila B; Montgomery ND; Kasonkanji E; Moses A; Nyasosela R; Mzumara S; Varela C; Chikasema M; Makwakwa V; Itimu S; Tomoka T; Kamiza S; Dhungel BM; Chimzimu F; Kampani C; Krysiak R; Richards KL; Shea TC; Liomba NG
PLoS One; 2016; 11(3):e0150445. PubMed ID: 26934054
[TBL] [Abstract][Full Text] [Related]
5. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma.
Simonelli C; Zanussi S; Cinelli R; Dal Maso L; Di Gennaro G; D'Andrea M; Nasti G; Spina M; Vaccher E; De Paoli P; Tirelli U
Clin Infect Dis; 2003 Sep; 37(6):820-7. PubMed ID: 12955644
[TBL] [Abstract][Full Text] [Related]
6. Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma.
Baiocchi OC; Colleoni GW; Navajas EV; Duarte LC; Alves AC; Andrade AL; Kerbauy J; Oliveira JS
Acta Oncol; 2002; 41(2):192-6. PubMed ID: 12102166
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Ratner L; Lee J; Tang S; Redden D; Hamzeh F; Herndier B; Scadden D; Kaplan L; Ambinder R; Levine A; Harrington W; Grochow L; Flexner C; Tan B; Straus D;
J Clin Oncol; 2001 Apr; 19(8):2171-8. PubMed ID: 11304769
[TBL] [Abstract][Full Text] [Related]
8. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
Barta SK; Lee JY; Kaplan LD; Noy A; Sparano JA
Cancer; 2012 Aug; 118(16):3977-83. PubMed ID: 22180164
[TBL] [Abstract][Full Text] [Related]
9. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
Ramos JC; Sparano JA; Chadburn A; Reid EG; Ambinder RF; Siegel ER; Moore PC; Rubinstein PG; Durand CM; Cesarman E; Aboulafia D; Baiocchi R; Ratner L; Kaplan L; Capoferri AA; Lee JY; Mitsuyasu R; Noy A
Blood; 2020 Sep; 136(11):1284-1297. PubMed ID: 32430507
[TBL] [Abstract][Full Text] [Related]
10. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Kaplan LD; Lee JY; Ambinder RF; Sparano JA; Cesarman E; Chadburn A; Levine AM; Scadden DT
Blood; 2005 Sep; 106(5):1538-43. PubMed ID: 15914552
[TBL] [Abstract][Full Text] [Related]
11. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
Toffoli G; Corona G; Cattarossi G; Boiocchi M; Di Gennaro G; Tirelli U; Vaccher E
Ann Oncol; 2004 Dec; 15(12):1805-9. PubMed ID: 15550586
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies.
Castillo JJ; Echenique IA
Am J Hematol; 2012 Mar; 87(3):330-3. PubMed ID: 22308010
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Pavlovsky M; Cubero D; Agreda-Vásquez GP; Enrico A; Mela-Osorio MJ; San Sebastián JA; Fogliatto L; Ovilla R; Avendano O; Machnicki G; Barreyro P; Trufelli D; Villanova P
JCO Glob Oncol; 2022 Mar; 8():e2100265. PubMed ID: 35486884
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.
Levine AM; Noy A; Lee JY; Tam W; Ramos JC; Henry DH; Parekh S; Reid EG; Mitsuyasu R; Cooley T; Dezube BJ; Ratner L; Cesarman E; Tulpule A
J Clin Oncol; 2013 Jan; 31(1):58-64. PubMed ID: 23169503
[TBL] [Abstract][Full Text] [Related]
15. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
Sparano JA; Hu X; Wiernik PH; Sarta C; Reddy DM; Hanau L; Henry DH
J Natl Cancer Inst; 1997 Feb; 89(4):301-7. PubMed ID: 9048834
[TBL] [Abstract][Full Text] [Related]
16. AIDS-lymphoma (ARL): one more step along the way.
Levine AM
Blood; 2013 Nov; 122(19):3244-6. PubMed ID: 24203926
[TBL] [Abstract][Full Text] [Related]
17. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
18. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
Ramos JC; Sparano JA; Rudek MA; Moore PC; Cesarman E; Reid EG; Henry D; Ratner L; Aboulafia D; Lee JY; Ambinder RF; Mitsuyasu R; Noy A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):180-190.e2. PubMed ID: 29426719
[TBL] [Abstract][Full Text] [Related]
19. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
20. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
